论文部分内容阅读
本研究探讨细胞因子诱导的自体杀伤(cytokine induced killer,CIK)细胞输注对造血系统恶性肿瘤老年患者免疫功能的影响及其与疗效的关系。采集20例造血系统恶性肿瘤老年患者外周血单个核细胞,在体外经重组干扰素-γ(IFN-γ)、白介素-2(IL-2)、抗CD3单克隆抗体诱导成CIK细胞,回输细胞数为(2-3)×109个,回输后第1-10天应用IL-2 100万单位/天,皮下注射。28天为1个疗程,共完成了136个周期的自体CIK细胞输注。观察治疗前后细胞免疫功能变化,结合肿瘤相关生物学指标、缓解情况、生活质量及生存期的变化进行疗效分析。结果表明,14例接受8个疗程的CIK细胞输注,6例接受4个疗程的输注,回输后所有患者未出现不良反应。CIK细胞治疗后外周血CD3+、CD3+CD8+、CD3+CD56+细胞比例明显升高(p<0.05),β2微球蛋白、LDH水平显著下降(p<0.05)。所有患者症状改善、生活质量显著提高(p<0.01)。11例达完全缓解,7例达部分缓解,2例疾病稳定。结论:自体CIK细胞输注可提高造血系统恶性肿瘤老年患者的细胞免疫功能且安全有效。
This study was aimed to investigate the effect of cytokine induced killer (CIK) cell infusion on the immune function of elderly patients with hematopoietic malignancies and its relationship with the therapeutic effect. Peripheral blood mononuclear cells from 20 patients with hematopoietic malignancies were collected and induced into CIK cells by recombinant interferon-γ (IFN-γ), interleukin-2 (IL-2) and anti-CD3 monoclonal antibodies The number of cells was (2-3) × 109, and 1 to 10 million units of IL-2 / day were administered subcutaneously 1-10 days post-infusion. 28 days for a course of treatment, completed a total of 136 cycles of autologous CIK cell infusion. The changes of cellular immune function before and after treatment were observed. The curative effect was analyzed according to the biological indicators of tumor, remission, quality of life and survival. The results showed that 14 patients received 8 courses of infusion of CIK cells, 6 patients received 4 courses of infusion, no adverse reactions after the return of all patients. The percentage of CD3 +, CD3 + CD8 + and CD3 + CD56 + cells in CIK cells was significantly increased (p <0.05) and the levels of β2 microglobulin and LDH were significantly decreased (p <0.05). All patients improved their symptoms and their quality of life improved significantly (p <0.01). Eleven patients achieved complete remission, 7 patients achieved partial remission, 2 patients were stable. CONCLUSION: Autologous CIK cell infusion can improve the cellular immune function of elderly patients with hematopoietic malignancies and is safe and effective.